3i maintains exit momentum with 2.3x pharma return
The London-listed firm has recorded its eighth exit this year with the secondary sale of Xellia Pharmaceuticals.
20 September 2013•2 mins read
The London-listed firm has recorded its eighth exit this year with the secondary sale of Xellia Pharmaceuticals.
